Mink Therapeutics, INC. (INKT) — SEC Filings

Overview

Mink Therapeutics, INC. (INKT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: MiNK Therapeutics, Inc. (INKT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $9,892,157, up from $8,321,698 in the prior year period, representing an 18.9% increase. The company's cash and cash equivalents surged to $14,281,212 as of September 30,

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 5 bearish, 27 neutral, 2 mixed. The dominant filing sentiment for Mink Therapeutics, INC. is neutral.

Filing Type Overview

Mink Therapeutics, INC. (INKT) has filed 21 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 1 SC 13G, 1 SC 13D with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (34)

• 8-K Filing — 8-K · Dec 8, 2025
• MiNK Therapeutics' Losses Widen Amidst Equity Raise, Going Concern Doubts — 10-Q · Nov 14, 2025 Risk: high
  MiNK Therapeutics, Inc. (INKT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $9,892,157, up from $8,321,698
• MiNK Therapeutics Relocates HQ to New York — 8-K · Sep 29, 2025 Risk: low
  MiNK Therapeutics, Inc. announced on September 23, 2025, a change in its principal executive offices to 149 Fifth Avenue, Suite 500, New York, NY 10010. The com
• MiNK Therapeutics Files 8-K on Operations and Financials — 8-K · Aug 14, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial stat
• MiNK Therapeutics' Cash Dwindles Amid Rising Losses, Reverse Split — 10-Q · Aug 14, 2025 Risk: high
  MiNK Therapeutics, Inc. (INKT) reported a net loss of $7.00 million for the six months ended June 30, 2025, an increase from a net loss of $6.52 million in the
• MiNK Therapeutics Files 8-K with Material Agreement — 8-K · Jul 15, 2025 Risk: medium
  On July 15, 2025, MiNK Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes f
• MiNK Therapeutics to be Acquired by 03 Life Sciences — 8-K · Jul 14, 2025 Risk: medium
  MiNK Therapeutics, Inc. announced on July 11, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expec
• MiNK Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 18, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on June 18, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as AgenTus
• MiNK Therapeutics Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its Results of Operations and Financial Condition, and including Financial Statements and Exh
• MiNK Therapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  MiNK Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its operations. Key
• MiNK Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025 Risk: medium
  MiNK Therapeutics, Inc. filed its definitive proxy statement on April 30, 2025, for the fiscal year ending December 31, 2024. The company, formerly known as Age
• MiNK Therapeutics Files 8-K — 8-K · Mar 18, 2025 Risk: low
  On March 18, 2025, MiNK Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 149 Fifth Avenue,
• MiNK Therapeutics Files 2024 10-K — 10-K · Mar 18, 2025 Risk: medium
  MiNK Therapeutics, Inc. filed its 2024 10-K on March 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as AgenTus The
• MiNK Therapeutics Files 8-K with Corporate Updates — 8-K · Jan 21, 2025 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting events as of January 17, 2025. The filing indicates amendments to articles of incorporation
• MiNK Therapeutics Files Definitive Proxy Statement — DEF 14A · Dec 20, 2024 Risk: low
  MiNK Therapeutics, Inc. filed its Definitive Proxy Statement (DEF 14A) on December 20, 2024, for its fiscal year ending December 31, 2025. The filing pertains t
• MiNK Therapeutics Files 8-K on Financials — 8-K · Nov 14, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on November 14, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and E
• MiNK Therapeutics Reports Q3 2024 Equity Changes, Agenus Agreement — 10-Q · Nov 14, 2024 Risk: medium
  MiNK Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported changes in its equity accounts, including an increase in A
• MiNK Therapeutics Appoints New Chief Medical Officer — 8-K · Oct 31, 2024 Risk: medium
  MiNK Therapeutics, Inc. announced on October 30, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer. Dr. Drachman previously served as C
• MiNK Therapeutics Appoints New CMO, Elects Director — 8-K · Oct 18, 2024 Risk: medium
  MiNK Therapeutics, Inc. announced on October 15, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Dr. Jennifer L.
• MiNK Therapeutics Faces Delisting Concerns — 8-K · Sep 13, 2024 Risk: high
  MiNK Therapeutics, Inc. filed an 8-K on September 13, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was form
• MiNK Therapeutics Faces Nasdaq Delisting Warning — 8-K · Aug 30, 2024 Risk: high
  MiNK Therapeutics, Inc. announced on August 27, 2024, that it received a notification from the Nasdaq Stock Market indicating non-compliance with listing rules.
• MiNK Therapeutics Files 8-K on Operations and Financials — 8-K · Aug 13, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing also includes financial stat
• MiNK Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  MiNK Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses related to Atlant Clinical Lt
• MiNK Therapeutics Files 8-K on Shareholder Votes — 8-K · Jun 17, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 12, 2024. The company, formerly k
• SC 13G Filing — SC 13G · May 22, 2024
• MiNK Therapeutics Files 8-K for Equity Sale — 8-K · May 16, 2024 Risk: medium
  MiNK Therapeutics, Inc. entered into a Material Definitive Agreement on May 13, 2024, related to the unregistered sale of equity securities. The company, former
• MiNK Therapeutics Files 8-K on Financials — 8-K · May 14, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing also includes financial stateme
• MiNK Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
  MiNK Therapeutics, Inc. (INKT) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. MiNK Therapeutics, Inc. filed a 10-Q for the quarter ended March 31
• MiNK Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
  MiNK Therapeutics, Inc. (INKT) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. MiNK Therapeutics will hold its 2024 Annual Meeting of Stockhol
• MiNK Therapeutics Files 8-K on Financials — 8-K · Mar 21, 2024 Risk: low
  MiNK Therapeutics, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing also includes financial state
• MiNK Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk: medium
  MiNK Therapeutics, Inc. (INKT) filed a Annual Report (10-K) with the SEC on March 21, 2024. MiNK Therapeutics, Inc. filed its 2023 Form 10-K on March 21, 2024.
• MiNK Therapeutics Faces Nasdaq Delisting Warning — 8-K · Feb 29, 2024 Risk: high
  MiNK Therapeutics, Inc. received a notice on February 23, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on the Nasd
• Insider Garo Armen Files SC 13D for MiNK Therapeutics — SC 13D · Feb 14, 2024 Risk: low
  Garo H. Armen filed an SC 13D on February 14, 2024, concerning MiNK Therapeutics, Inc. common stock, which has a par value of $0.00001 per share and CUSIP 60369
• MiNK Therapeutics Reports New Material Agreement & Financial Obligation — 8-K · Feb 14, 2024 Risk: medium
  MiNK Therapeutics, Inc. filed an 8-K on February 14, 2024, reporting an event that occurred on February 12, 2024. The filing indicates the company entered into

Related Companies

AGEN · MNKK

Frequently Asked Questions